The unchanging mortality gap for people with schizophrenia
- 1 August 2009
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 374 (9690), 590-592
- https://doi.org/10.1016/s0140-6736(09)61072-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)The Lancet, 2009
- UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study)Archiv Fur Psychiatrie Und Nervenkrankheiten, 2009
- Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studySchizophrenia Research, 2008
- Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Schizophrenia Research, 2008
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.British Journal of Psychology, 2006
- Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant SchizophreniaSchizophrenia Bulletin, 2005
- Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 DiabetesPublished by Physicians Postgraduate Press, Inc ,2002
- Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of SchizophreniaAmerican Journal of Psychiatry, 2002
- Antipsychotic-Induced Weight Gain: A Comprehensive Research SynthesisAmerican Journal of Psychiatry, 1999